Navigation Links
Depression not discussed during rheumatoid arthritis doctor visits
Date:2/1/2008

Patients with rheumatoid arthritis (RA), the most common chronic inflammatory arthritis, are twice as likely as other individuals to experience depression. Although depression in primary care has been well studied, no studies have examined whether rheumatologists and RA patients discuss depression during medical visits. A new study published in the February issue of Arthritis Care & Research (http://www.interscience.wiley.com/journal/arthritiscare) found that patients whose activities were more restricted due to their arthritis were more than twice as likely to have moderately severe to severe symptoms of depression. It also found that few depressed patients discussed their condition with their rheumatologists and the subject was always brought up by the patients as opposed to the physicians.

Led by Betsy Sleath, of the University of North Carolina at Chapel Hill, NC, the study included 200 RA patients from four rheumatology clinics with eight participating doctors. Patient visits were audiotaped and patients were interviewed after their medical visits using a questionnaire to measure their mental status.

The results showed that almost 11% of the patients in the study had moderately severe to severe symptoms of depression and that those who were rated as being more restricted in their normal activities were significantly more likely to have these symptoms. Furthermore, only 1 in 5 of the patients who showed symptoms discussed depression with their rheumatologists and they were always the ones to bring up the topic. Even when depression was brought up, it was often not discussed at any length.

When patients visit their rheumatologists, their main focus is their RA, yet such chronic diseases can greatly impact a patients psychosocial well-being. In addition, many RA patients see their rheumatologists more often then their primary care physician and depression can also affect a patients adherence to treatment regimens. For these reasons the authors suggest that it is important for rheumatologists to consider addressing both the RA and the depression when they see their patients. The authors note that some physicians may not feel comfortable discussing depression with their patients, but they should consider having their office staff administer a brief depression screening before the patients visits in order to identify problems early on.

In addition to screening for depression, the authors suggest it is important for patients to have access to appropriate treatment. Rheumatologists can treat the depression themselves, refer patients to a mental health professional, or communicate with the patients primary care physician to coordinate a treatment plan. Also, given how common depression is in these patients, rheumatology training programs should educate physicians about the importance of screening for and treating depression.

Failure to detect and treat depression may compromise patients adherence to regimens and, ultimately, their health outcomes, the authors conclude. Future research should examine patient- and physician-reported barriers to communicating about depression in rheumatology practices and use these findings to design innovative interventions that can be delivered effectively in busy rheumatologist practices.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Blue Cross of California Launches Maternity Depression Program
2. Depression and anxiety can double chances of heart ailments
3. Depression, Obesity Coexist in Many Middle-Aged Women
4. Walk away menopausal anxiety, stress and depression
5. Realistic Expectations Help Ward Off Holiday Depression
6. Kaiser Permanente -- Group Health study shows depression worsens HIV treatment
7. Treating Depression Cuts Diabetes Death Risk
8. Blue Cross Blue Shield of Michigan Foundation Funds Study Exploring Link between Heart Disease and Depression
9. Lack of Light and Seasonal Depression - Whats the Link? From the Harvard Health Letter
10. Venlafaxine extended-release effective for patients with major depression
11. New studies on cancer and schizophrenia, depression and heart disease, trauma and autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: